Mondego Bio Lda is an immuno-oncology company headquartered in Lisbon that has just emerged from stealth. The firm is focused on developing novel cancer treatments that leverage the body’s immune system. Although still early in its corporate life cycle, Mondego Bio’s progress attracted significant investor interest, culminating in a sizeable Series A raise. The €20 million infusion will be used to advance the company’s research and development programs in immuno-oncology. No operating metrics such as revenue, clinical trial data, or user numbers have been disclosed. The company’s debut out of stealth and immediate funding underscore the market’s appetite for innovative oncology solutions. Additional strategic or commercial partnerships were not mentioned in the available information.

Total raised

$24M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2025